We are live on ! Find out more
DNTH icon

Dianthus Therapeutics

102 hedge funds and large institutions have $729M invested in Dianthus Therapeutics in 2025 Q2 according to their latest regulatory filings, with 18 funds opening new positions, 29 increasing their positions, 40 reducing their positions, and 14 closing their positions.

New
Increased
Maintained
Reduced
Closed

369% more call options, than puts

Call options by funds: $2.68M | Put options by funds: $572K

29% more first-time investments, than exits

New positions opened: 18 | Existing positions closed: 14

6% more capital invested

Capital invested by funds: $685M → $729M (+$43.1M)

4.22% more ownership

Funds ownership: 117.38%121.6% (+4.2%)

4% more funds holding

Funds holding: 98102 (+4)

0% more funds holding in top 10

Funds holding in top 10: 66 (0)

28% less repeat investments, than reductions

Existing positions increased: 29 | Existing positions reduced: 40

Holders
102
Holders Change
+4
Holders Change %
+4.08%
% of All Funds
1.34%
Holding in Top 10
6
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
0.08%
New
18
Increased
29
Reduced
40
Closed
14
Calls
$2.68M
Puts
$572K
Net Calls
+$2.11M
Net Calls Change
+$3.03M

DNTH Hedge Fund Activity: Q2 2025 in Review

102 of the 7,596 institutional investors tracked by Wall St. Rank reported a position in Dianthus Therapeutics (DNTH) for Q2 2025, worth a combined $729M — up 6.3% from $685M a quarter earlier.

Buyers outnumbered sellers: 18 funds opened new DNTH positions and 14 closed out — a net gain of 4 holders — while 29 added to existing stakes and 40 trimmed.

The largest buyer was Vestal Point Capital, adding an estimated $28.1M. The largest seller was VR Adviser, cutting an estimated $14M.

  • 102 institutional investors held Dianthus Therapeutics (DNTH) as of Q2 2025, up from 98 in Q1 2025.
  • Funds reported $729M of Dianthus Therapeutics stock for Q2 2025, up 6.3% quarter-over-quarter.
  • 18 funds opened new Dianthus Therapeutics positions in Q2 2025 and 14 closed out, a net change of +4 holders.
  • The largest Dianthus Therapeutics buyer in Q2 2025 was Vestal Point Capital, an estimated $28.1M added.
  • The largest Dianthus Therapeutics seller in Q2 2025 was VR Adviser, an estimated $14M sold.

Based on aggregated 13F filings for Q2 2025.